On July 25, GeLongHui reported that the board of directors audit committee of Zai Lab (09688.HK) will review and approve the unaudited interim performance of the company and its subsidiaries for three and six months ending June 30, 2024, prepared in accordance with US GAAP and applicable rules of the US Securities and Exchange Commission on Tuesday, August 6, 2024 (Eastern Time in the United States) / Wednesday, August 7, 2024 (Hong Kong Time) and publish it.
再鼎医药(09688.HK)董事会将于8月7日审议中期业绩
The board of directors of Zai Lab (09688.HK) will review the interim results on August 7th.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.